Beauty Health Co. Elects New Directors, Adjusts Executive Pay

TL;DR

Beauty Health Co. shakes up board with two new directors and revises exec pay packages.

AI Summary

Beauty Health Company announced on August 26, 2024, changes in its board of directors and executive compensation arrangements. Specifically, the company elected two new directors, Dr. Jessica Wu and Ms. Michelle Freidman, to its Board, effective immediately. Additionally, the company entered into new employment agreements with its Chief Executive Officer, Marisa Plescia, and Chief Financial Officer, Michael Moskowitz, detailing their compensation and benefits.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Changes in board and executive compensation can introduce uncertainty regarding future strategy and leadership stability.

Key Players & Entities

• Beauty Health Company (company) — Registrant
• Dr. Jessica Wu (person) — Newly elected director
• Ms. Michelle Freidman (person) — Newly elected director
• Marisa Plescia (person) — Chief Executive Officer
• Michael Moskowitz (person) — Chief Financial Officer
• August 26, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.0001 — tered Class A Common Stock, par value $0.0001 per share SKIN The Nasdaq Capital Marke

Filing Documents

• skin-20240826.htm (8-K) — 27KB
• 0001628280-24-038962.txt ( ) — 179KB
• skin-20240826.xsd (EX-101.SCH) — 2KB
• skin-20240826_def.xml (EX-101.DEF) — 15KB
• skin-20240826_lab.xml (EX-101.LAB) — 26KB
• skin-20240826_pre.xml (EX-101.PRE) — 15KB
• skin-20240826_htm.xml (XML) — 3KB

From the Filing

skin-20240826 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2024 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 2165 Spring Street Long Beach , CA (Address of principal executive offices) 90806 (Zip Code) ( 800 ) 603-4996 (Registrant's telephone number, including area code) Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Class A Common Stock, par value $0.0001 per share SKIN The Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( 240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 26, 2024, Dr. Julius Few notified the board of directors (the "Board") of The Beauty Health Company (the "Company") of his decision to resign as a director of the Company, effective immediately. Prior to his resignation, Dr. Few also served on the Nominating and Corporate Governance Committee of the Board. Dr. Few's resignation was not the result of any dispute or disagreement with the Company, its management, the Board, or any committee of the Board on any matter relating to the operations, policies, or practices of the Company. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 30, 2024 The Beauty Health Company By: /s/ Michael Monahan Name: Michael Monahan Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR